Citi Suggests Accumulating Shares of Walt Disney (DIS) Ahead of Q1 Report
DIS Hot Sheet
Rating Summary:11 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Citi maintains a 'Buy' on Walt Disney (NYSE: DIS) price target raised from $42 to $44.
Analyst, Jason Bazinet, suggests buying shares of DIS ahead of the company's Q1 release. Bazinet raised FY13 EPS estimates from $3.25 to $3.35, citing a lower share count.''
Shares of DIS have been higher all session, thanks in part to an earlier upgrade by Davenport, which went from Neutral to Buy, and raised its price target to $46.
For an analyst ratings summary and ratings history on Walt Disney click here. For more ratings news on Walt Disney click here.
Shares of Walt Disney closed at $40.00 yesterday, with a 52 week range of $28.19-$44.34.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
Analyst, Jason Bazinet, suggests buying shares of DIS ahead of the company's Q1 release. Bazinet raised FY13 EPS estimates from $3.25 to $3.35, citing a lower share count.''
Shares of DIS have been higher all session, thanks in part to an earlier upgrade by Davenport, which went from Neutral to Buy, and raised its price target to $46.
For an analyst ratings summary and ratings history on Walt Disney click here. For more ratings news on Walt Disney click here.
Shares of Walt Disney closed at $40.00 yesterday, with a 52 week range of $28.19-$44.34.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- Barclays Cuts Estimates and Price Target on ADP (ADP); Mixed Data From Investor Day
- Needham & Company Maintains a 'Hold' on Teva Pharma (TEVA); Adjusting Estimates
Create E-mail Alert Related Categories
Analyst Comments, UpgradesRelated Entities
Citi, DavenportSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
